Please enable JavaScript.
Coggle requires JavaScript to display documents.
Targeted Therapy - Coggle Diagram
Targeted Therapy
A.
Tyrosine Kinase Inhibitors
Imatinib
- tx GI stromal tumors (GIST) expressing the c-kit tyrosine kinase
Dasatinib
- approved for use in CML and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to imatinib therapy.
Nilotinib
- approved for chronic phase and accelerated phase CML with resistance or intolerance to prior therapy
Bosutinib
- approved for the treatment of adult patients with chronic, accelerated, or blast phase Ph chromosome positive CML with resistance or intolerance to prior therapy.
Ponatinib
- approved for adult patients with chronic, accelerated, or blast phase CML that is resistant or intolerant to prior TKI therapy
B.
Growth Factor Receptor Inhibitors
Cetuximab
- also approved for use in combination with radiation therapy in patients with locally advanced head and neck cancer.
A/E
- acneiform skin rash, hypersensitivity infusion reaction, and hypomagnesemia
Panitumumab
- approved for use in combination with FOLFOX chemotherapy in the front line treatment of metastatic CRC
A/E
- Acneiform skin rash and hypomagnesemia
Necitumumab
- use in combination with gemcitabine and cisplatin chemotherapy for the treatment of squamous NSCLC.
Erlotinib
- approved as first line treatment of metastatic NSCLC in patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations
Afatinib
- approved for the first line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 substitution mutations.
Osimertinib
- tx metastatic EGFR T790M mutant NSCLC following progression on or after EGFR tyrosine kinase inhibitor therapy.
C.
Vascular Endothelial Growth Factor Receptor Inhibitor
Bevacizumab
- can be safely and effectively combined with 5 FU -, irinotecan -, and oxaliplatin based chemotherapy in the treatment of metastatic colorectal cancer.
Ziv aflibercept
- approved in combination with the FOLFIRI regimen for patients with metastatic colorectal cancer that has progressed on oxaliplatin based chemotherapy.
Ramucirumab
- approved for advanced gastric or gastroesophageal junction adenocarcinoma, metastatic NSCLC, and metastatic CRC.
Sorafenib
- advanced renal cell cancer and is also approved for advanced hepatocellular cancer.
Sunitinib
- approved for the treatment of advanced renal cell cancer and for the treatment of gastrointestinal stromal tumors after disease progression on or with intolerance to imatinib.
Pazopanib
- treatment of advanced renal cell cancer.